BRVE - Braveheart Bio, Inc.
Price:
--
--
|
PRICE TARGET:
$45.25
DETAILS
HIGH:
$48.00
LOW:
$40.00
MEDIAN:
$46.50
CONSENSUS:
$45.25
UPSIDE:
93.62%
About Braveheart Bio, Inc. (http://www.braveheart.bio)
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Travis Murdoch | CEO, President & Director | 1985 | $482,509 USD |
| Michele A. Anderson | Chief Development Officer | 1967 | $474,746 USD |
| James Paul Rickey | Chief Financial Officer | 1979 | $455,178 USD |
| Brittany de Temple | Senior Vice President of Development Operations | – | – |
| Carlos L. Del Rio FACC | Senior Vice President of Cardiovascular Research & Translational Science | – | – |
| Emil deGoma | Chief Medical Officer | 1976 | – |
| Marc Evanchik | Chief Scientific Officer | 1973 | – |
| Natalie Dement | VP & Head of Legal | – | – |
| Steph Palencia | Associate Director of Human Resources & Office Manager | – | – |
| Timothy Y. Zhou | Director of Corporate Development | – | – |
| Tyler Chavez | Chief Business Officer | 1989 | – |